Quantcast

Latest Proton pump inhibitors Stories

2009-06-01 08:39:24

Hospitalized patients who are given acid-suppressive medications are 30 percent more likely to develop pneumonia during their hospital stay, a new study found. Between 40 and 70 percent of hospitalized patients receive acid-suppressive medications, such as proton-pump inhibitors, which has raised concern among some researchers who say the drugs are sometimes prescribed for symptoms that are not supported by research and data. Researchers in Boston studied the records of nearly 64,000 patients...

2009-05-27 08:17:49

Hospitalized patients who receive acid-suppressive medications such as a proton-pump inhibitor have a 30 percent increased odds of developing pneumonia while in the hospital, according to a study in the May 27 issue of JAMA. With the introduction of proton-pump inhibitors, used primarily in the treatment of ulcers and gastroesophageal reflux disease, the use of acid-suppressive medications has increased significantly over the last several years, with estimates that between 40 percent and...

2009-05-14 15:30:00

CINCINNATI, May 14 /PRNewswire/ -- In response to the FDA's approval of Prevacid OTC(R) 24HR, The Procter & Gamble Company issued the following statement: (Photo: http://www.newscom.com/cgi-bin/prnh//NY17325 ) "Prilosec OTC(R) is the #1 doctor and pharmacist recommended over-the-counter heartburn remedy in the U.S.," said Tim Brown - General Manager, P&G Personal Health Care North America. "Procter & Gamble built the OTC PPI market and since 2003, millions of consumers have...

2009-05-14 06:00:00

- This approval will provide greater convenience and broader access to an effective treatment option to the 50 million Americans(1) suffering from frequent heartburn - Once-daily, prescription-strength Prevacid(R) 24HR is the first OTC proton pump inhibitor approved for the treatment of frequent heartburn in the US since 2003 - Prescription-strength Prevacid 24HR treats frequent heartburn for a full 24 hours BASEL, Switzerland, May 14 /PRNewswire/ -- Novartis announced today that...

2009-05-07 08:47:52

Proton pump inhibitors interfere with anti-clotting protection of clopidogrel The anti-clotting action of the medication clopidogrel (Plavix) can be compromised by common drugs for the treatment of heartburn and ulcers resulting in a roughly 50% increase in the combined risk of hospitalization for heart attack, stroke and other serious cardiovascular illnesses, according to a new study presented yesterday at the Society for Cardiovascular Angiography and Interventions (SCAI) 32nd Annual...

2009-05-06 23:39:13

The anti-clotting action of the medication clopidogrel -- Plavix -- can be compromised by common drugs for the treatment of heartburn, U.S. researchers said. Principal investigator Eric J. Stanek of Medco Health Solutions in Franklin Lakes, N.J., said the study specifically focused on the effects of proton pump inhibitors -- omeprazole or Prilosec; esomeprazole or Nexium; pantoprazole or Protonix; and lansoprazole or Prevacid. Together those drugs accounted for about 96 percent of proton...

2009-05-06 12:45:00

- Four of the most commonly used proton pump inhibitors raise risk of heart attack and stroke for patients taking Plavix(R) and increase healthcare costs - Drug interaction increases annual hospital costs by nearly 40 percent FRANKLIN LAKES, N.J., May 6 /PRNewswire-FirstCall/ -- Four of the most commonly prescribed heartburn medications reduce the benefit associated with clopidogrel, a widely used antiplatelet medication also known by its brand name, Plavix. These findings by researchers...

2009-05-06 12:30:00

LAS VEGAS, May 6 /PRNewswire/ -- Results of the Clopidogrel Medco Outcomes Study presented today during SCAI's Annual Scientific Sessions found the anti-clotting benefits of clopidogrel (Plavix) may be reduced when taken concurrently with commonly used heartburn medications called proton pump inhibitors (PPIs). In the study, patients taking clopidogrel and a PPI experienced a: 50% increase in the combined risk of hospitalization for heart attack, stroke, unstable angina, or repeat...

2009-05-04 07:00:00

- Company Also Submits sNDA for NEXIUM Capsules for Risk Reduction of Low-Dose Aspirin-Associated Peptic Ulcer - WILMINGTON, Del., May 4 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for a product combining low dose aspirin with esomeprazole magnesium for the risk reduction of low dose aspirin-associated gastric and/or duodenal ulcers in patients at risk....

2009-04-23 08:10:30

 In a new study, published in the May issue of Elsevier's Experimental Neurology (www.elsevier.com/locate/yexnr), scientists at the University of British Columbia have discovered that drugs commonly used to treat ulcers have significant neuroprotective properties, which appear to be enhanced when used in combination with ibuprofen, a widely used anti-inflammatory drug."Our results show that proton pump inhibitors are also antiinflammatory agents. They open up an entirely new application...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.